載入...
Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy
Brentuximab vedotin, an antibody drug conjugate that delivers monomethyl auristatin E into CD-30 expressing cells is FDA approved for the treatment of patients with Hodgkin lymphoma after the failure of autologous stem cell transplantation or at least 2 prior multi-agent chemotherapy regiments. This...
Na minha lista:
| 發表在: | Case Rep Oncol |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
S. Karger AG
2017
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5685419/ https://ncbi.nlm.nih.gov/pubmed/29158727 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000479224 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|